Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:80878
Name IDH-wildtype glioblastoma
Definition A glioblastoma that is characterized by high cellularity, high mitotic activity, necrosis or microvascular proliferation and that lacks mutations in IDH genes.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer cell type cancer high grade glioma malignant astrocytoma glioblastoma IDH-wildtype glioblastoma


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600E Vemurafenib IDH-wildtype glioblastoma predicted - sensitive detail...
BRAF V600E Dabrafenib + Trametinib IDH-wildtype glioblastoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03158389 Phase Ib/II Vismodegib Alectinib Idasanutlin Temsirolimus Atezolizumab Palbociclib APG101 NCT Neuro Master Match - N²M² (NOA-20) (N²M²) Completed DEU 0
NCT04910022 Phase Ib/II NMS-03305293 + Temozolomide Lomustine Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma Recruiting USA | ITA 2
NCT04945148 Phase II Metformin + Temozolomide Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide (OPTIMUM) Not yet recruiting ITA | FRA 0
NCT05267106 Phase II Pemigatinib Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) Recruiting USA | ITA | GBR | FRA | ESP | DEU 3
NCT05432375 Phase I Tinostamustine Study of Tinostamustine for Adjuvant Treatment of Glioblastoma Recruiting ESP 1
NCT05432518 Phase I Olaparib Palbociclib Afatinib Everolimus Dasatinib GBM Personalized Trial Recruiting CAN 0
NCT05463848 Phase II Olaparib + Pembrolizumab + Temozolomide Pembrolizumab Surgical Pembro +/- Olaparib w TMZ for rGBM Recruiting USA 0
NCT05465954 Phase II NT-I7 + Pembrolizumab Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma Recruiting USA 0
NCT05734560 Phase Ib/II 2141 V-11 + D2C7-IT D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients Recruiting USA 0
NCT05765812 Phase Ib/II Debio 0123 + Temozolomide A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma Recruiting USA | ESP 1
NCT05879250 Phase II WP1066 WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Not yet recruiting USA 0
NCT05917145 Phase I WSD-0628 Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors Not yet recruiting USA 0
NCT05986851 Phase II Azeliragon Azeliragon in MGMT Unmethylated Glioblastoma Recruiting USA 0
NCT06095375 Phase I Regorafenib + Temozolomide Regorafenib in Combination With Temozolomide With or Without Radiotherapy in Patients With Newly Diagnosed MGMT-Methylated, IDH Wild-type Glioblastoma. (REGOMA-2) Recruiting ITA 0
NCT06097975 Phase I Ipilimumab + Nivolumab A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma (NEO-GLITIPNI) Not yet recruiting BEL 0